Loading
Loading
Research Overview
Potent ERRα/γ (oestrogen-related receptor) agonist; activates oxidative metabolism gene programs mimicking aspects of endurance exercise, increasing fat oxidation and mitochondrial biogenesis in skeletal muscle in rodent models.
Overview
SLU-PP-332 functions as an agonist at ERRα and ERRγ, constitutively active transcriptional regulators of mitochondrial and oxidative metabolic gene networks. Preclinical research has used this compound to investigate how pharmacological activation of ERR signalling influences mitochondrial biogenesis, skeletal muscle oxidative capacity, and energy metabolism in animal models.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, slu-pp-332 (errα/errγ agonist) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Potent ERRα/γ (oestrogen-related receptor) agonist; activates oxidative metabolism gene programs mimicking aspects of endurance exercise, increasing fat oxidation and mitochondrial biogenesis in skeletal muscle in rodent models.
Support
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
